DROFEN Hosts Senior Executive From Wockhardt To Discuss High-Speed Pen Injector Final Assembly Solutions

Shanghai, China – June 12, 2026 – DROFEN MACHINERY EQUIPMENT CO., LTD, a leading turnkey system supplier of automated assembly lines for injection pens and pre-filled syringes, today welcomed a Senior Vice President from Wockhardt, a major Indian multinational pharmaceutical and biotechnology company, for an in-depth technical exchange and facility tour.

 

The high-level visit focused on addressing the escalating global demand for insulin and GLP-1 therapies, and the critical role of advanced fill-finish equipment in scaling up production capacity reliably.

 

 

DROFEN's engineering team began by presenting the company's pre-assembly platform, which assembles all injection-molded plastic components into a complete pen mechanism at 160 parts per minute. 

 

The pre-assembly line integrates dose dial sleeves, clutch springs, drive sleeves, plunger rods, and pen housings through a fully automated process using 26 servo axes and vision-guided orientation systems.

 

The Wockhardt executive reviewed the pre-assembly system's 5-Cell independent architecture, which ensures that a single-Cell fault results in only 20% capacity loss rather than a full line stoppage - a critical design principle for maintaining high OEE on continuous production runs.

 

 

The primary focus of the visit was DROFEN's final assembly line  - the critical stage where the pre-filled drug cartridge is integrated into the assembled pen mechanism, transforming it into a finished, patient-ready injection pen.

 

A key topic of interest was preventing micro-cracks in the pen housing during the critical stage of pressing the pen body into the cartridge holder. This is the highest-risk operation in the entire assembly process: if the pen housing cracks during press-in, the drug cartridge - often containing high-value biologics worth significantly more than the device itself - must be scrapped entirely.

 

DROFEN presented its proprietary servo-driven pressing stations equipped with real-time force-displacement monitoring. This advanced system continuously tracks the force profile during the pressing operation at millisecond resolution. By detecting anomalies such as misaligned threads, oversized cartridges, or material inconsistencies instantly, the system aborts the operation before glass breakage or plastic cracking occurs - enabling unit-level rejection without halting the entire line or destroying the drug product.

 

"The final assembly stage is where the stakes are highest," explained Jordan Xu, Managing Director at DROFEN. "In pre-assembly, a rejected unit costs only the plastic components - perhaps a few cents. In final assembly, a rejected unit means losing the entire drug cartridge. This is why our force-displacement monitoring operates at millisecond resolution - we must detect the problem before the crack propagates."

 

 

A central theme of the visit was how to maintain Overall Equipment Effectiveness (OEE) above 85% on high-speed pen assembly lines operating at 160 parts per minute. When a unit is judged as NG (No Good) during final assembly, the entire drug cartridge must be scrapped - making OEE not just an efficiency metric but a direct cost control imperative.

 

"At 160 PPM, every second of unplanned downtime costs 2.67 assembled pens. A 15-minute jam that would be tolerable on a 30 PPM line translates to 2,400 lost units," explained Mr. Xu. "This is why OEE must be engineered into the system architecture from day one, not optimized after commissioning."

 

Mr. Xu presented DROFEN's published engineering methodology for achieving OEE ≥ 85%, which addresses all three OEE factors through deliberate architectural decisions:

 

Availability ≥ 92% is achieved through a 5-Cell independent architecture where each Cell operates autonomously with its own dedicated servo motors and PLC function blocks. Combined with full servo drive (26 axes, eliminating mechanical cam wear) and an MTTR of under 2 minutes by design, the platform sustains availability levels that mechanical cam-driven systems cannot match.

 

Performance ≥ 95% is maintained through a three-level electronic cam architecture with Profinet IRT synchronization (jitter < 1 μs), eliminating speed fluctuation from mechanical backlash. All vision inspections are completed on-the-fly during part motion, with processing times between 8–20 ms - well within the 375 ms cycle time - ensuring line speed is never compromised by quality checks.

Quality ≥ 98% is guaranteed through a seven-layer inspection system employing a "Detect → Reject → Confirm" triple closed-loop architecture, including 100% piece-by-piece KISTLER torque testing and real-time press force closed-loop control.

 

The detailed technical breakdown of this methodology is available in DROFEN's published article: Achieving OEE ≥ 85% on a 160 PPM Injection Pen Pre-Assembly Line: Engineering Methodology.

 

 

The Wockhardt representative conducted a thorough review of DROFEN's comprehensive validation documentation. DROFEN demonstrated its full alignment with global standards, including GAMP 5 guidelines, ensuring that its automated assembly lines seamlessly pass rigorous GMP validation processes (IQ/OQ/PQ) required by international regulatory bodies.

 

The review covered Design Qualification (DQ), Factory Acceptance Testing (FAT), Site Acceptance Testing (SAT), and complete traceability documentation - confirming that DROFEN's equipment is fully prepared for deployment in GMP-regulated manufacturing environments worldwide.

 

 

The visit also highlighted the strategic advantage of DROFEN's corporate structure. As a subsidiary of Wanhai Medical, a leading manufacturer of medical devices and injection pen housings, DROFEN offers a unique value proposition that extends beyond equipment supply.

 

"We are not just an equipment vendor; we are a project delivery partner," explained Mr. Xu. "By combining Wanhai Medical's expertise in injection pen design, molding, and regulatory registration with DROFEN's advanced assembly automation, we provide a unified platform. This synergy allows us to optimize the interface between the plastic components and the assembly machinery, drastically reducing integration risks and accelerating time-to-market for our clients."

 

This integrated approach - offering both the injection pens and the turnkey assembly lines (pre-assembly and final assembly) - positions DROFEN as a comprehensive solutions provider capable of supporting pharmaceutical companies from device selection through to full-scale commercial production.

 

Wockhardt is a leading Indian multinational pharmaceutical and biotechnology company headquartered in Mumbai, with 12 manufacturing facilities, 3 research centers, and full-fledged operations in the USA, UK, Ireland, and France. The company's Biologicals in Diabetes division has been developing and manufacturing biological products and insulin delivery devices since 2004, serving global markets with its patented pen injector platforms.

 

DROFEN MACHINERY EQUIPMENT CO., LTD is a specialized system supplier focusing on two core product lines: turnkey automated assembly lines for insulin and GLP-1 injection pens (pre-assembly and final assembly), and comprehensive pre-filled syringe (PFS) filling and packaging lines. Backed by the Wanhai Medical platform, DROFEN provides complete project delivery including equipment, pen devices, regulatory validation support, and platform integration services to global pharmaceutical manufacturers and CDMOs.

 

•Automatic Insulin Pen Assembly Line: Complete Guide to High-Speed Manufacturing 

•Achieving OEE ≥ 85% on a 160 PPM Injection Pen Pre-Assembly Line

•Overcoming Fill-Finish Capacity Bottlenecks in Automated Pen Injector Assembly Lines - Pharmaceutical Technology